Abacus FCF Advisors LLC Decreases Position in AbbVie Inc. $ABBV

Key Points

• Abacus FCF Advisors LLC cut its stake in AbbVie by 19.3% in Q4, selling 24,405 shares and ending with 101,863 shares worth about $23.28 million (AbbVie is ~3.0% of the fund and its 4th-largest holding).
• AbbVie received an FDA Complete Response Letter (CRL) for trenibotulinumtoxinE due to manufacturing/process issues, delaying potential commercialization and creating near-term regulatory uncertainty for the neurotoxin program.
• Despite the CRL, AbbVie beat quarterly expectations (EPS $2.71 vs. $2.65; revenue $16.62B, +10% y/y), set FY2026 EPS guidance of $14.37–$14.57, and declared a $1.73 quarterly dividend (3.5% yield).

Abacus FCF Advisors LLC cut its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 19.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 101,863 shares of the company's stock after selling 24,405 shares during the quarter. AbbVie accounts for about 3.0% of Abacus FCF Advisors LLC's holdings, making the stock its 4th biggest holding. Abacus FCF Advisors LLC's holdings in AbbVie were worth $23,275,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Chelsea Counsel Co. purchased a new stake in shares of AbbVie during the third quarter worth about $26,000. Westend Capital Management LLC purchased a new stake in AbbVie in the 4th quarter worth approximately $29,000. Texas Capital Bancshares Inc TX bought a new stake in shares of AbbVie in the 3rd quarter worth approximately $31,000. WestEnd Advisors LLC grew its position in shares of AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock worth $32,000 after buying an additional 85 shares during the last quarter. Finally, Caitlin John LLC bought a new position in AbbVie in the 3rd quarter worth $33,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Trading Down 1.1%

AbbVie stock opened at $198.71 on Friday. AbbVie Inc. has a 12 month low of $176.57 and a 12 month high of $244.81. The stock has a fifty day simple moving average of $216.68 and a two-hundred day simple moving average of $222.33. The firm has a market cap of $351.35 billion, a price-to-earnings ratio of 84.20, a PEG ratio of 0.72 and a beta of 0.38.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analysts' expectations of $16.39 billion. During the same period last year, the firm posted $2.16 earnings per share. AbbVie's revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 14.21 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.5%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio is presently 293.22%.

Wall Street Analysts Forecast Growth

Several analysts have commented on ABBV shares. Cantor Fitzgerald lowered their price objective on shares of AbbVie from $250.00 to $240.00 and set an "overweight" rating for the company in a report on Wednesday, April 8th. The Goldman Sachs Group reiterated a "neutral" rating and set a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 11th. Evercore reduced their price target on AbbVie from $232.00 to $228.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 4th. Finally, Piper Sandler decreased their price objective on AbbVie from $299.00 to $294.00 and set an "overweight" rating for the company in a report on Thursday. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $253.19.

Insider Buying and Selling at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.06% of the stock is owned by corporate insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a major strategic investment: a $1.4 billion, AI-enabled manufacturing campus in Durham, NC that will create hundreds of permanent jobs and supports capacity for immunology, neuroscience and oncology medicines. This strengthens manufacturing footprint and long-term growth/production capacity. Article Title
• Positive Sentiment: Canaccord initiated coverage with a Buy and $262 price target (recent coverage highlighted AbbVie as a buy on pullback), providing bullish analyst support and upside from current levels. Analyst upgrades can buoy sentiment and attract inflows. Article Title
• Positive Sentiment: AbbVie struck an exclusive licensing deal with Haisco for development of pain medicines, expanding its pipeline and potential addressable market for pain therapeutics. Partnership deals can add optionality to future revenue. Article Title
• Neutral Sentiment: Wall Street previews and model-level estimates for Q1 (sales and key metric breakdowns) are circulating ahead of AbbVie’s April 29 earnings; these projections set expectations traders will use for the report. Meeting or beating estimates could stabilize the stock. Article Title
• Neutral Sentiment: Analysts and media continue to discuss AbbVie as a dividend-growth candidate and a long-term defensive healthcare holding; this maintains baseline investor interest but is unlikely to move shares sharply near-term. Article Title
• Negative Sentiment: The U.S. FDA issued a Complete Response Letter (CRL) for AbbVie’s trenibotulinumtoxinE (TrenibotE) — citing manufacturing/process issues rather than new clinical trials. AbbVie said it will respond and believes it can address comments, but the CRL delays potential commercialization and near-term revenue expectations for the neurotoxin program. Article Title
• Negative Sentiment: Multiple outlets report the CRL is tied to manufacturing concerns; while AbbVie noted no additional clinical studies were requested, regulatory manufacturing issues create uncertainty on timing and cost to obtain approval — a near-term headwind for sentiment. Article Title

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.